

PTO/SB/08A (10-01)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SEA	A1	US 6,238,903		05/29/2001	Krystal	
	A2	US				
	A3	US				
	A4	US				
	A5	US				
	A6	US				
	A7	US				
	A8	US				
	A9	US				
	A10	US				
	A11	US				
	A12	US				
	A13	US				
	A14	US				
	A15	US				
	A16	US				
	A17	US				
	A18	US				
	A19	US				
	A20	US				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
SEA	B1	WO	03033517	04/24/2003	The University of British Columbia		
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						
	B8						

Examiner
Signature

Sabiha N. Bazy

Date
Considered

12/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Boreham, Christopher J., et al., "Structure and origin of the two major monoaromatic hydrocarbons in a tasmanite oil shale from Tasmania, Australia," Organic Geochemistry (1995) 23(5):461-6.	
	C2	Corey, Elias J., et al., "Exceptionally simple enantioselective syntheses of chiral hexa- and tetracyclic polyprenoids of sedimentary origin," Angewandte Chemie, Intl. Ed. (1998) 37(8):1126-1128.	
	C3	Damen, J.E., et al., "Multiple forms of the SH2-containing Inositol phosphatase, SHIP, are generated by c-terminal truncation," Blood (1998) 92(4):1199.	
	C4	Database CA 'Online! Sorokina, I.B., et al. "Estrogen and antineoplastic activity in a series of transformed estrone and estradiol analogs," Izvestiya Akademii Nauk SSSR, Seriya Biologicheskaya (1973), vol. 5, pgs. 664-70, CODEN IANBAM; 0002-3329, Database accession no. 80:91450. (Document No. XP002230773)	
SA	C5	Freeman, Katherine H., et al., "The effect of aromatization on the isotopic compositions of hydrocarbons during early diagenesis," Organic Geochemistry (1994) 21(10-11):1037-1049.	
1	C6	Goclik, Eva, et al., "Palerol from the tropical Marine Sponge Dactylospongia elegans," Journal of Natural Products (2000), 63:8, 1150-1152. (Document No. XP002254980)	
	C7	Harring, Scott, et al., "Polyene cascade cyclizations mediate by BF ₃ ·OEt ₂ ·CH ₃ NO ₂ . An unusually efficient method of polycyclic intermediates via cationic initiations at non-functionalized 3 alkenes. An application to the total synthesis of (racemic)-taxodione," Tetrahedron, (1994) 50:31, 9229-9254 (Document No. XP002230772)	
	C8	He, W, et al., "Novel cytokine release inhibitors. Part III: truncated analogs of tripterine," Bioorganic & Medicinal Chemistry Letters, Oxford, BG (1998) 8:24, 3659-3664.	
	C9	Helgason, C.D., et al. "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span," Genes Dev. (1998) 12:1610-1620.	
	C10	Helgason, C.D., et al. "A dual role for src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of B lymphocytes in SHIP ^{-/-} mice," J. Exp. Med. (2000) 191(5):781-794.	
	C11	Herz, Werner, et al., "Resin Acids. XV. Oxidative transformations of the levopimaric acid-acetylenedicarboxylic ester adduct," Resin Acids. (1969) 34(5):1257-1266, J. Org. Chem. Vol 34, No 5 (1969)	
	C12	Huber, M., et al., "The role of SHIP in growth factor induced signaling," Prog Biophys Mol Biol. (1999) 71(3-4) 423-34.	
	C13	Ishihara, Kazuaki, et al., "Enantioselective biomimetic cyclization of homo-polyprenylidarens. A new entry to (+)-podocarpa-8,11,13-triene diterpenoids and (-)-tetracyclic polyprenoid of sedimentary origin," J. of the American Chem. Soc. (2001) 123:1505-1506.	
	C14	Ishihara, Kazuaki, et al., "Enantio- and diastereoselective stepwise cyclization of polyprenoids induced by chiral and achiral LBAs. A new entry to (-)-ambrox, (+)-podocarpa-8,11,13-triene diterpenoids, and (-)-tetracyclic polyprenoid of sedimentary origin," J. of the American Chem. Soc. (2002) 124:3647-3655.	

Examiner
Signature


Sabiha N. Qazi

Date
Considered

12/21/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issuue number(s), publisher, city and/or country where published.	T 2
	C15	Kwak, J.H., et al., "Sesquiterpene quinols/quinones from the micronesian sponge petrospongla metachromia," J. Nat. Prod. (2000) 63(8):1153-56.	
	C16	Liu, Ling, et al., "A specific inhibitor of SH2-containing inositol-5-phosphatase (SHIP)," (2001) Blood 98:1225 LY288975 (Abstract No. 1225).	
	C17	Mitome, Hidemichi, et al., "Dactyloquinones a and B, new sesquiterpenoid quinones from the okinawan marine sponge <i>Dactylospongia elegans</i> ," J. Nat. Prod. (2001) 64:1506-1508.	
SD	C18	Mitome, Hidemichi, et al., "Dactyloquinones c, d and e novel sesquiterpenoid quinones, from the okinawa marine sponge, <i>Dactylospongia elegans</i> ," Tetrahedron (2002) 58:1693-1696.	
	C19	Mukku, Venugopal J.R., et al., "New sesquiterpene quinols from a micronesian sponge, <i>aka</i> sp," J. Nat. Prod. (2003) 66:686-689.	
	C20	O'Farrell, A.M. et al., "Stat3-dependent induction of p19 ^{INK4d} by il-10 contributes to inhibition of macrophage proliferation," J. Immunol (2000) 164:4607-4615.	
	C21	Rosales, Viale, et al., "Regioselective palladium-catalyzed alkylation of allylic halides with benzylic grignard reagents. Two-step synthesis of abietane terpenes and tetracyclic polyprenoid compounds," J. of Organic Biochem (2002) 67(4):1167-1170.	
	C22	Sattler, M., et al., "BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis," Mol Cell Biol (1999) 19(11):7473-7480.	
	C23	Schaeffer, Phillippe, et al., "Novel optically active hydrocarbons in sediments: evidence for an extensive biological cyclization of higher regular polyprenols," Angew. Chem. Int. Ed. Engl. (1994) 33(11):1166-1169 (Angew. Chem. (1994) 106:1235-8).	

Examiner
Signature

Sabita N. Baze

Date
Considered

12/21/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.